Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 0.66 |
| ▸ | CCNC | P24863 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23807116 | 1.00 | IRAK4 (0.66) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL23945447 | 1.00 | IRAK4 (0.66) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL23806199 | 0.90 | IRAK4 (0.54) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL23805966 | 0.90 | IRAK4 (0.54) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL23806217 | 0.90 | IRAK4 (0.54) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL23805970 | 0.89 | IRAK4 (0.54) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL23806164 | 0.89 | IRAK4 (0.54) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL23806201 | 0.89 | IRAK4 (0.54) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL23807760 | 0.89 | IRAK4 (0.55) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL21996736 | 0.89 | IRAK4 (0.55) | IRAK4CCNCCDK8CLK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885CCNC 3820/4885CDK8 646/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885CCNC 3820/4885CDK8 646/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885CCNC 3820/4885CDK8 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.